Real-World Evidence Study Supports Efficacy of Monoclonal Antibody for Infant RSV

blue digital binary data on computer screen. Close-up shallow DOF

Real-world evidence (RWE) presented at this year’s European Society for Paediatric Infectious Diseases meeting show that administration of nirsevimab, a monoclonal antibody (mAb), prevented hospitalizations in infants infected with respiratory syncytial virus (RSV). Data from over 8,000 babies was taken from the 2022-2023 RSV season.

According to Catherine Eckford, “Real-world data from the Phase IIIb trial also showed that nirsevimab reduced the incidence of hospitalisations due to severe RSV-related LRTD by 75.71 percent. The mAb demonstrated a reduction of 58.04 percent in the incidence of all-cause LRTD hospitalisation compared to infants who received no RSV intervention.”

To read more, click here.

(Source: European Pharmacy Review, May 15^th, 2023)